.jpg)
Oct 31, 2020
Aravax appoints Financial Executive Thomas Ulmer to Board of Directors
01 November, 2020, Melbourne, Victoria - Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly...
Sep 29, 2019
Aravax receives positive pre-IND feedback from FDA on PVX108 Phase 2 trial plans.
30 September 2019, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on developing the first therapy for...
Jun 3, 2019
Aravax Presents Additional Positive PVX108 Phase 1 Clinical Trial Safety Results at EAACI 2019
June 4, 2019, Melbourne, Victoria –Trial results demonstrate excellent PVX108 safety profile in patients with prior anaphylaxis and...
May 28, 2019
Aravax to Present Additional PVX108 Phase 1 Clinical Trial Safety Results at EAACI 2019
May 28, 2019, Melbourne, Victoria – Data show that PVX108 demonstrates exceptional safety in adults with peanut allergy Aravax, a...
Feb 24, 2019
Australian peanut therapy developer Aravax reveals positive Phase I trial results at AAAAI
February 25, 2019, Melbourne, Australia – Melbourne biotech to take its revolutionary peanut allergy treatment to Phase II clinical...
Feb 12, 2019
Aravax to Present PVX108 Phase 1 Clinical Trial Results at AAAAI 2019 Annual Meeting
February 13, 2019, MELBOURNE, Australia – Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly...